Organization | National Academy of Sciences of Belarus

National Academy of Sciences of Belarus Report issue

Academic/Hospital Phase 2

Founded: Belarus Belarus (1929)

Organization Overview

First Clinical Trial

2009

NCT04457037

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2022

Timeline

NOW

Now

Alternative names

Ass prof of 2nd Department of Surgical Diseases of BSMU | Director, the Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus | Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus | the Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus

Active Ingredients

Drugs in Phase 2 Trials (14)

allogeneic mesenchymal stem cells (2 trials)

allogenic mesenchymal stem cell derived from olfactory mucosa (4 trials)

autologous adipose-derived mesenchymal stem cells (4 trials)

autologous dendritic cells primed with muc-1/wt-1 peptides (1 trial)

autologous dermal cells (1 trial)

autologous keratinocytes (1 trial)

autologous mesenchymal stem cells (3 trials)

autologous regulatory t cells (1 trial)

autologous skin fibroblasts (1 trial)

cytokine induced killer cells (1 trial)

human retinal progenitor cells (1 trial)

parathyroid cells (1 trial)

stem cells (1 trial)

tolerogenic dendritic cells (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Burns (Phase 2)

Chronic Periodontitis (Phase 2)

Corneal Diseases (Phase 2)

Corneal Ulcer (Phase 2)

Endometritis (Phase 2)

Enuresis (Phase 2)

Gingival Recession (Phase 2)

Gynatresia (Phase 2)

Lung Diseases, Interstitial (Phase 2)

Lupus Erythematosus, Systemic (Phase 2)

Periodontitis (Phase 2)

Pneumonia (Phase 2)

Pneumonia, Viral (Phase 2)

Ulcer (Phase 2)

Urinary Bladder Neoplasms (Phase 2)

Urinary Incontinence (Phase 2)

Urinary Incontinence, Stress (Phase 2)

Wounds and Injuries (Phase 2)

Overview

Highest Phase: Phase 2
# of Trials: 22
# of Trial APIs: 14